This Applied Digital Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
Benzinga (Wed, 7-Jan 7:09 AM ET)
Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million
PRNewswire (Wed, 17-Dec 7:00 AM ET)
Compugen Reports Third Quarter 2025 Results
PRNewswire (Mon, 10-Nov 7:00 AM ET)
Compugen to Participate in Stifel 2025 Healthcare Conference
PRNewswire (Tue, 4-Nov 7:00 AM ET)
Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025
PRNewswire (Mon, 27-Oct 7:01 AM ET)
PRNewswire (Mon, 13-Oct 7:00 AM ET)
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
Compugen Ltd. - trades on the NASDAQ stock market under the symbol CGEN.
As of January 8, 2026, CGEN stock price declined to $1.64 with 329,426 million shares trading.
CGEN has a beta of 1.20, meaning it tends to be more sensitive to market movements. CGEN has a correlation of 0.11 to the broad based SPY ETF.
CGEN has a market cap of $153.36 million. This is considered a Micro Cap stock.
Last quarter Compugen Ltd. - reported $2 million in Revenue and -$.07 earnings per share. This fell short of revenue expectation by $-778,598 and exceeded earnings estimates by $.02.
In the last 3 years, CGEN traded as high as $3.03 and as low as $.53.
The top ETF exchange traded funds that CGEN belongs to (by Net Assets): SPDW, GWX.
CGEN has underperformed the market in the last year with a return of +2.5%, while the SPY ETF gained +18.4%. In the last 3 month period, CGEN fell short of the market, returning -6.8%, while SPY returned +3.3%. However, in the most recent 2 weeks CGEN has outperformed the stock market by returning +6.5%, while SPY returned -0.1%.
CGEN support price is $1.64 and resistance is $1.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CGEN shares will trade within this expected range on the day.
